Approach to the Patient With Thyroid Nodules: Considering GLP-1 Receptor Agonists
The DOI matches its Crossref record; 76 of the 79 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 receptor agonists (GLP1RAs) have rapidly changed the landscape of diabetes and obesity treatment. Enthusiasm for their use is tempered with concerns regarding their risk for inducing C-cell tumors based on preclinical studies in rodents. A black-box warning from the US Food and Drug Administration recommends against using GLP1RA in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2A or 2B (MEN2), providing clear guidance regarding this cohort of patients. However, emerging data also suggest an increased incidence of differentiated thyroid cancer (DTC) in patients treated with these agents. Other studies, though, have not confirmed an association between GLP1RAs and DTC. With conflicting results concerning thyroid cancer risk, there is no clear consensus regarding the optimal approach to screening patients prior to initiating the medications and/or evaluating for thyroid cancer during GLP1RA treatment. Within the context of patient cases, this review will summarize the existing data, describe ongoing controversies, and outline future areas for research regarding thyroid cancer risk with GLP1RA use.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, all GLP-1s have FDA black box warnings for a potential association with thyroid cancer and long-term data on the safety of the higher doses used for obesity treatment are not yet available [19].”
From Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US (2025) · cites this paper as [19]
Citations
Cites
Management of a Solitary Thyroid Nodule
Desforges, J. F., & Mazzaferri, E. L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302253280807 · Cited by 1,412
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Lin, J. S., Bowles, E. J. A., Williams, S. B., & Morrison, C. C. (2017) · JAMA · doi:10.1001/jama.2017.0562 · Cited by 1,082
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874
Plasma Insulin Response to Oral and Intravenous Glucose Administration1
ELRICK, H., STIMMLER, L., HLAD, C. J., & ARAI, Y. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-10-1076 · Cited by 857
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672
Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s009 · Cited by 662
Bergenstal, R. M., Wysham, C., MacConell, L., Malloy, J., Walsh, B., Yan, P., Wilhelm, K., Malone, J., & Porter, L. E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60590-9 · Cited by 608
Pratley, R. E., Nauck, M., Bailey, T., Montanya, E., Cuddihy, R., Filetti, S., Thomsen, A. B., Søndergaard, R. E., & Davies, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60307-8 · Cited by 586
International Union of Pharmacology. XXXV. The Glucagon Receptor Family
Mayo, K. E., Miller, L. J., Bataille, D., Dalle, S., Göke, B., Thorens, B., & Drucker, D. J. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.1.6 · Cited by 506
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477
Buteau, J., Foisy, S., Joly, E., & Prentki, M. (2003) · Diabetes · doi:10.2337/diabetes.52.1.124 · Cited by 411
DeFronzo, R. A., Okerson, T., Viswanathan, P., Guan, X., Holcombe, J. H., & MacConell, L. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802418851 · Cited by 373
Fehmann, H. C. (1992) · Endocrinology · doi:10.1210/en.130.1.159 · Cited by 337
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
Bezin, J., Gouverneur, A., Pénichon, M., Mathieu, C., Garrel, R., Hillaire-Buys, D., Pariente, A., & Faillie, J.-L. (2023) · Diabetes Care · doi:10.2337/dc22-1148 · Cited by 320
Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells
Lee, Y.-S., & Jun, H.-S. (2014) · Metabolism · doi:10.1016/j.metabol.2013.09.010 · Cited by 315
Screening for Thyroid Cancer: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Bibbins-Domingo, K., Grossman, D. C., Curry, S. J., Barry, M. J., Davidson, K. W., Doubeni, C. A., Epling, J. W., Kemper, A. R., Krist, A. H., et al. (2017) · JAMA · doi:10.1001/jama.2017.4011 · Cited by 313
Alves, C., Batel-Marques, F., & Macedo, A. F. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.09.008 · Cited by 186
Effects of Exenatide on Systolic Blood Pressure in Subjects With Type 2 Diabetes
Okerson, T., Yan, P., Stonehouse, A., & Brodows, R. (2010) · American Journal of Hypertension · doi:10.1038/ajh.2009.245 · Cited by 186
Madsen, L. W., Knauf, J. A., Gotfredsen, C., Pilling, A., Sjögren, I., Andersen, S., Andersen, L., Sietske de Boer, A., Manova, K., Barlas, A., et al. (2012) · Endocrinology · doi:10.1210/en.2011-1864 · Cited by 161
Glucagon Like Peptide-1 Receptor Expression in the Human Thyroid Gland
Gier, B., Butler, P. C., Lai, C. K., Kirakossian, D., DeNicola, M. M., & Yeh, M. W. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2407 · Cited by 157
Impact of Overweight and Obesity on US Papillary Thyroid Cancer Incidence Trends (1995–2015)
Kitahara, C. M., Pfeiffer, R. M., Sosa, J. A., & Shiels, M. S. (2020) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz202 · Cited by 142
d'Herbomez, M., Caron, P., Bauters, C., Do Cao, C., Schlienger, J.-L., Sapin, R., Baldet, L., Carnaille, B., Wémeau, J.-L., & _, _. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0566 · Cited by 134
Koehler, J. A., Kain, T., & Drucker, D. J. (2011) · Endocrinology · doi:10.1210/en.2011-1201 · Cited by 128
Hu, W., Song, R., Cheng, R., Liu, C., Guo, R., Tang, W., Zhang, J., Zhao, Q., Li, X., & Liu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.927859 · Cited by 127
Glucagon‐like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study
Pasternak, B., Wintzell, V., Hviid, A., Eliasson, B., Gudbjörnsdottir, S., Jonasson, C., Hveem, K., Svanström, H., Melbye, M., & Ueda, P. (2024) · BMJ · doi:10.1136/bmj-2023-078225 · Cited by 125
Glucagon-Like-Peptide-1 Receptor Expression in Normal and Diseased Human Thyroid and Pancreas
Waser, B., Blank, A., Karamitopoulou, E., Perren, A., & Reubi, J. C. (2015) · Modern Pathology · doi:10.1038/modpathol.2014.113 · Cited by 119
Silverii, G. A., Monami, M., Gallo, M., Ragni, A., Prattichizzo, F., Renzelli, V., Ceriello, A., & Mannucci, E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15382 · Cited by 113
Cao, C., Yang, S., & Zhou, Z. (2019) · Endocrine · doi:10.1007/s12020-019-02055-z · Cited by 99
Karanikas, G., Moameni, A., Poetzi, C., Zettinig, G., Kaserer, K., Bieglmayer, C., Niederle, B., Dudczak, R., & Pirich, C. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030709 · Cited by 95
Nauck, M. A., Jensen, T. J., Rosenkilde, C., Calanna, S., Buse, J. B., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Diabetes Care · doi:10.2337/dc17-1825 · Cited by 94
Kratzsch, J., Petzold, A., Raue, F., Reinhardt, W., Bröcker-Preuβ, M., Görges, R., Mann, K., Karges, W., Morgenthaler, N. G., Luster, M., et al. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.151688 · Cited by 90
Zhao, H., Wang, L., Wei, R., Xiu, D., Tao, M., Ke, J., Liu, Y., Yang, J., & Hong, T. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12291 · Cited by 88
Semaglutide and cancer: A systematic review and meta-analysis
Nagendra, L., BG, H., Sharma, M., & Dutta, D. (2023) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102834 · Cited by 86
Prorok, P. C., Chamberlain, J., Day, N. E., Hakama, M., & Miller, A. (1984) · International Journal of Cancer · doi:10.1002/ijc.2910340102 · Cited by 84
Zhao, H., Wei, R., Wang, L., Tian, Q., Tao, M., Ke, J., Liu, Y., Hou, W., Zhang, L., Yang, J., et al. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00017.2014 · Cited by 77
Utility of Serum Procalcitonin for Screening and Risk Stratification of Medullary Thyroid Cancer
Machens, A., Lorenz, K., & Dralle, H. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1278 · Cited by 74
Screening for differentiated thyroid cancer in selected populations
Lamartina, L., Grani, G., Durante, C., Filetti, S., & Cooper, D. S. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30324-9 · Cited by 72
Crespel, A., De Boisvilliers, F., Gros, L., & Kervran, A. (1996) · Endocrinology · doi:10.1210/endo.137.9.8756532 · Cited by 67
Hegedüs, L., Sherman, S. I., Tuttle, R. M., von Scholten, B. J., Rasmussen, S., Karsbøl, J. D., Daniels, G. H., & for the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Diabetes Care · doi:10.2337/dc17-1956 · Cited by 67
Bea, S., Son, H., Bae, J. H., Cho, S. W., Shin, J., & Cho, Y. M. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15292 · Cited by 64
Putting GLP-1 RAs and Thyroid Cancer in Context: Additional Evidence and Remaining Doubts
Thompson, C. A., & Stürmer, T. (2023) · Diabetes Care · doi:10.2337/dci22-0052 · Cited by 51
Kahaly, G. J., Algeciras‐Schimnich, A., Davis, T. E., et al. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.270009 · Cited by 45
Self-citationExenatide modulates tumor–endothelial cell interactions in human ovarian cancer cells
Kosowska, A., Gallego-Colon, E., Garczorz, W., Kłych-Ratuszny, A., Aghdam, M. R. F., Woz´niak, M., Witek, A., Wróblewska-Czech, A., Cygal, A., Wojnar, J., et al. (2017) · Endocrine Connections · doi:10.1530/ec-17-0294 · Cited by 45
Mali, G., Ahuja, V., & Dubey, K. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13259 · Cited by 44
Costante, G., & Filetti, S. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0344 · Cited by 43
Bethel, M. A., Patel, R. A., Thompson, V. P., Merrill, P., Reed, S. D., Li, Y., Ahmadi, S., Katona, B. G., Gustavson, S. M., Ohman, P., et al. (2019) · Diabetes Care · doi:10.2337/dc18-2028 · Cited by 43
Eftekhari, S., Montazeri, H., & Tarighi, P. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173102 · Cited by 43
He, L., Zhang, S., Zhang, X., Liu, R., Guan, H., & Zhang, H. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s150701 · Cited by 40
Jung, M. J., & Kwon, S. K. (2014) · Endocrinology and Metabolism · doi:10.3803/enm.2014.29.4.536 · Cited by 38
Wu, T., Zhang, Y., Shi, Y., Yu, K., Zhao, M., Liu, S., & Zhao, Z. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01202-1 · Cited by 38
Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review
Espinosa De Ycaza, A. E., Brito, J. P., McCoy, R. G., Shao, H., & Singh Ospina, N. (2024) · Thyroid · doi:10.1089/thy.2023.0530 · Cited by 37
Li, X.-N., Bu, H.-M., Ma, X.-H., Lu, S., Zhao, S., Cui, Y.-L., & Sun, J. (2016) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0042-112368 · Cited by 36
Ma, B., Wang, X., Ren, H., Li, Y., Zhang, H., Yang, M., & Li, J. (2023) · BMC Cancer · doi:10.1186/s12885-023-11077-w · Cited by 36
Exenatide use and incidence of pancreatic and thyroid cancer: A retrospective cohort study
Liang, C., Bertoia, M. L., Ding, Y., Clifford, C. R., Qiao, Q., Gagne, J. J., & Dore, D. D. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13597 · Cited by 35
Mao, D., Cao, H., Shi, M., Wang, C. C., Kwong, J., Li, J. J. X., Hou, Y. J., Ming, X., Lee, H. M., Tian, X. Y., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103242 · Cited by 33
GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells
Zhang, X., Zhang, L., Wang, B., Zhang, X., Gu, L., Guo, K., Zhang, X., & Zhou, Z. (2023) · Cellular and Molecular Biology · doi:10.14715/cmb/2023.69.14.37 · Cited by 32
Increased Plasma Calcitonin in Early Acute Renal Failure
Ardaillou, R., Beaufils, M., Nivez, M.-P., ISAAC, R., Mayaud, C. M., & Sraer, J. (1975) · Clinical Science · doi:10.1042/cs0490301 · Cited by 30
Pu, Z., Yang, Y., Qin, S., Li, X., Cui, C., & Chen, W. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2810259 · Cited by 30
Effect of GLP1R agonists taspoglutide and liraglutide on primary thyroid C-cells from rodent and man
Boess, F., Bertinetti-Lapatki, C., Zoffmann, S., George, C., Pfister, T., Roth, A., Lee, S. M. L., Thasler, W. E., Singer, T., & Suter, L. (2013) · Journal of Molecular Endocrinology · doi:10.1530/jme-12-0186 · Cited by 29
Dore, D. D., Seeger, J. D., & Chan, K. A. (2012) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098612446473 · Cited by 28
Funch, D., Mortimer, K., Ziyadeh, N. J., Seeger, J. D., Zhou, L., Ng, E., Ross, D., Major-Pedersen, A., Bosch-Traberg, H., Gydesen, H., et al. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s305496 · Cited by 24
Prevalence of Subclinical Papillary Thyroid Cancer by Age: Meta-analysis of Autopsy Studies
Arroyo, N., Bell, K., Hsiao, V., Fernandes‐Taylor, S., Alagöz, O., Zhang, Y., Davies, L., & Francis, D. O. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac468 · Cited by 22
Zhang, Y., Cheng, J., Li, J., He, J., Li, X., & Xu, F. L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.793530 · Cited by 14
Makunts, T., Joulfayan, H., & Abagyan, R. A. (2024) · JMIRx Med · doi:10.2196/55976 · Cited by 14
Lunati, M. E., Grancini, V., Colombo, C., Palmieri, E., Resi, V., Perrino, M., Orsi, E., & Fugazzola, L. (2015) · Metabolism · doi:10.1016/j.metabol.2015.09.010 · Cited by 12
Medullary Thyroid Carcinoma Surveillance Study: A Case-Series Registry
Hale, P. M., Ali, A. K., Buse, J., McCullen, M. K., Ross, D., Sabol, M., Tuttle, R. M., & Stemhagen, A. (2020) · Thyroid · doi:10.1089/thy.2019.0591 · Cited by 9
Goldenberg, R., & Jain, A. (2023) · Diabetes Care · doi:10.2337/dc22-2300 · Cited by 9
Smits, M. M., & van Raalte, D. H. (2023) · Diabetes Care · doi:10.2337/dc23-0134 · Cited by 7
Endo, M., Roth, M. Y., Tylee, T. S., DeSantis, A., & Hirsch, I. B. (2023) · Diabetes Care · doi:10.2337/dc22-2454 · Cited by 6
Cited by
Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103363 · Cited by 157
Bansal, M. B., Patton, H. M., Morgan, T. R. M., Carr, R. M., Dranoff, J. A., & Allen, A. M. (2025) · Hepatology · doi:10.1097/hep.0000000000001608 · Cited by 192
Pearson, S. D., Whaley, C. M., & Emond, S. K. (2025) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2025-0083 · Cited by 55
“In addition, all GLP-1s have FDA black box warnings for a potential association with thyroid cancer and long-term data on the safety of the higher doses used for obesity treatment are not yet available [19] .”
Valencia-Rincón, E., Rai, R., Chandra, V., & Wellberg, E. A. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194743 · Cited by 43
“Nonetheless, the FDA issued a warning for most GLP-1R–targeted therapies for patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome, which remains in place today (41).”
Wang, L., Zhang, L., Ma, R., Zhang, Y., Chang, Q., & Yin, D. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf053 · Cited by 29
Metadata
- Authors
- Kelly, C. A., & Sipos, J. A.
- Affiliations
- University Hospitals of Cleveland (US)
- The Ohio State University Wexner Medical Center (US)
- ORCID
- Sipos, Jennifer A
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2024-10-14
- Volume
- 110
- Issue
- 6
- Pages
- e2080-e2087
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W4403398649
- Cited by
- 30
- References
- 79
- Citations by year
- 2026: 20 · 2025: 10
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Keywords
- GLP-1 receptor agonists, thyroid nodules, medullary thyroid carcinoma, multiple endocrine neoplasia type 2, differentiated thyroid cancer, thyroid cancer risk, black box warning, thyroid cancer screening, obesity treatment, diabetes treatment
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Thyroid Neoplasms, Thyroid Nodule, Carcinoma, Neuroendocrine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.